Illumina同分子诊断公司Burning Rock签署合作协议开发新型肿瘤药品

  今日，Illumina公司和分子诊断公司Burning Rock宣布了一项合作协议，将基于测序仪器在中国的市场来共同合作开发新型的肿瘤药品。
  作为这项协议的一部分，Illumina将提供新一代测序技术的仪器组件及试剂，而位于广州的Burning Rock公司将提供它们的核酸抽提技术、文库制备及数据分析软件。
  Burning Rock公司的创立者及CEO Yusheng Han表示，目前我们正在努力研究开发，目的是在中国促进基因组技术的临床应用；而基于新一代测序技术的肿瘤学分子诊断技术，包括无创诊断等，都可以应用于临床中，同时我们也希望可以改善医院的一些临床实践方法。
  最后Illumina公司的高级副总裁和首席医疗官Rick Klausner表示，两家公司的合作或将会增加中国获得肿瘤诊断解决方案的机会。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Illumina, Burning Rock Partner for Oncology MDx

Illumina and molecular diagnostics firm Burning Rock announced today that they will codevelop oncology products based on Illumina's sequencing instruments for the Chinese market.

As part of the agreement, Illumina will provide NGS instrument components and reagents and Guangzhou, China-based Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software.

"We have been working to promote the clinical application of genomic technology in China," Burning Rock Founder and CEO Yusheng Han said in a statement. "Oncology molecular diagnosis based on NGS, including non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals."

The collaboration will "increase access to oncology diagnosis solutions in China," Rick Klausner, Illumina's senior VP and chief medical officer, said in a statement.